[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610137":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":47,"centralContacts":11,"locations":50,"responsibleParty":64,"collaborators":11,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":11,"eligibilityCriteria":72,"healthyVolunteers":73,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":11,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":91,"whyStopped":11,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",[8,17],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1","EXPERIMENTAL",null,[13,14,15,16],"Drug: Repotrectinib","Drug: Metformin","Drug: Digoxin","Drug: Rosuvastatin",{"label":18,"type":10,"description":11,"interventionNames":19},"Cohort 2",[13,20,21,22],"Drug: Bupropion","Drug: Flurbiprofen","Drug: Omeprazole",[24,29,32,35,38,41,44],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"DRUG","Repotrectinib","Specified dose on specified days",[9,18],{"type":25,"name":30,"description":27,"armGroupLabels":31,"otherNames":11},"Metformin",[9],{"type":25,"name":33,"description":27,"armGroupLabels":34,"otherNames":11},"Digoxin",[9],{"type":25,"name":36,"description":27,"armGroupLabels":37,"otherNames":11},"Rosuvastatin",[9],{"type":25,"name":39,"description":27,"armGroupLabels":40,"otherNames":11},"Bupropion",[18],{"type":25,"name":42,"description":27,"armGroupLabels":43,"otherNames":11},"Flurbiprofen",[18],{"type":25,"name":45,"description":27,"armGroupLabels":46,"otherNames":11},"Omeprazole",[18],[48],{"name":5,"affiliation":5,"role":49},"STUDY_DIRECTOR",[51],{"facility":52,"status":11,"city":53,"state":54,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":11},"Local Institution - 0001","Daytona Beach","Florida","32117-5116","United States","US",{"type":59,"coordinates":60},"Point",[61,62],-81.02283,29.21081,{"lat":62,"lon":61},{"type":65,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100610137","phase-1-study-to-evaluate-the-effect-of-repotrectinib-on-the-drug-levels-of-transporter-and-cyp-p450-probe-substrates-in-healthy-adult-participants-100610137",false,"NCT07223671","Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants","Phase 1, 2-Cohort, Open-label, Fixed-sequence, Drug-drug Interaction Study to Evaluate the Effect of Repotrectinib on the Pharmacokinetics of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants","Inclusion Criteria\n\n* Participants must have a body mass index (BMI) of 18.0 to 32.0 kg\u002Fm2 and should be between the ages of 18-60 years inclusive.\n* Healthy female (as assigned at birth) participants who are individuals not of childbearing potential (INOCBP) and healthy males with no clinically significant deviation from normal for the following: medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory assessment results as determined by the investigator.\n\nExclusion Criteria\n\n* Participants must not have a significant history of clinical manifestation of any metabolic, allergic, dermatological, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, psychiatric, neoplastic, or genitourinary abnormalities\u002Fdiseases as determined by the investigator or designee.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.",true,"ALL","18 Years","60 Years",{"count":78,"type":79},30,"ACTUAL","INTERVENTIONAL",[82],"PHASE1","The purpose of the study if to evaluate the effect of Repotrectinib on the drug levels of transporter and CYP P450 probe substrates in healthy adult participants.",[85],"Healthy Volunteers",[87,88,89,90],"Drug-Drug Interactions","Pharmacokinetics","Transporter Probe Substrates","CYP P450 Probe Substrates","COMPLETED","2026-03-24",{"date":94,"type":79},"2026-03-27",{"date":96,"type":79},"2025-12-31",{"date":98,"type":79},"2026-03-19",{"name":5,"class":6},1]